

A novel *Bacteroides metallo-β-lactamase* (MBL) and its gene (*crxA*) in *Bacteroides xylanisolvens* revealed by genomic sequencing and functional analysis

József Sóki^{1*}, Uwe Lang², Ulrike Schumacher³, István Nagy^{4,5}, Ágnes Berényi¹, Tamás Fehér⁴, Katalin Burián¹ and Elisabeth Nagy¹

¹Department of Medical Microbiology, Albert Szent-Györgyi Health Center and Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary; ²Medical Care Centre Laboratory Münster, Münster, Germany; ³Medical Care Centre Laboratory Ravensburg, Ravensburg, Germany; ⁴Institute of Biochemistry, Biological Research Centre, Loránd Eötvös Research Network, Szeged, Hungary; ⁵SEQOMICS Ltd, Mórahalom, Hungary

*Corresponding author. E-mail: soki.jozsef@med.u-szeged.hu

Received 10 October 2021; accepted 16 February 2022

Objectives: We sought to characterize the carbapenem resistance mechanism of *Bacteroides xylanisolvens* 14880, an imipenem-resistant strain from Germany, and assess its prevalence.

Methods: Antimicrobial susceptibilities were determined using agar dilution or Etest methodology and specific imipenemase activity was detected. The genomic sequence of *B. xylanisolvens* 14880 was determined and analysed for antibiotic resistance genes and genomic islands. We also used gene transfer to a carbapenem susceptible host, along with 5'-RACE, conventional PCR with capillary sequencing and RT-PCR-based screening.

Results: *B. xylanisolvens* 14880 displayed resistance to carbapenems and produced high specific imipenemase activity. Its genomic sequence was 6.1 Mbp and a class B1 β-lactamase gene (termed *crxA*) was detected in it. *crxA* was carried on a putative genomic island with insertion sequence (IS) elements and a putative GNAT (Gcn5-like acetyltransferase) toxin gene. Promoter localization by 5'-RACE and gene targeting to an imipenem-susceptible *Bacteroides* host indicated that it is activated by an IS1380-like IS element and it can confer carbapenem resistance. The PCR screening of *Bacteroides* strains showed that *crxA* was specific to *B. xylanisolvens* with a carriage rate of 16.7%.

Conclusions: *B. xylanisolvens* strains can harbour a carbapenem resistance gene, which has many similarities to the '*cfiA* system': metallo-β-lactamase (MBL), IS element activation, carriage of a GNAT toxin gene, specific for a unique *Bacteroides* species with a significant prevalence.

Introduction

The most effective antibiotics that target anaerobic *Bacteroides* infections are carbapenems, metronidazole, β-lactam/β-lactamase combinations and tigecycline.¹ The carbapenem resistance of *Bacteroides fragilis* is mediated by the CfiA metallo-β-lactamase (MBL), which is activated by the integration of insertion sequence (IS) elements upstream of the resistance gene.² The *cfiA* gene is contained on a DNA segment ('*cfiA* element') that is specific for division II strains and it is always accompanied by two ORFs encoding acetylases (GNAT – Gcn5-like acetyltransferase and XAT/*vat* – xenobiotic acetylase, which are now thought to form a toxin-antitoxin pair).^{3–5} The CfiA-mediated resistance mechanism can limit the treatment of *B. fragilis* infections, but, so far, there have been no major

concerns regarding non-*fragilis* *Bacteroides* species in terms of carbapenem resistance, despite its detection; in the USA it has been reported only at a very low prevalence (usually between 0% and 0.5% for different species).⁶ Additionally, except for a few cases, namely a *Parabacteroides distasonis* from the USA,⁷ two other *Bacteroides* strains isolated from faeces in our laboratory⁸ and a *Bacteroides thetaiotaomicron* strain also from the USA,⁹ no carbapenem-resistant, non-*fragilis* *Bacteroides* strain has been characterized in more detail.

Bacteroides xylanisolvens was described in 2008 based on the xylanolytic activity of some *Bacteroides* strains isolated from human faecal samples.¹⁰ It is very closely related to *Bacteroides ovatus* so that it is scarcely distinguishable from it by MALDI-TOF MS or 16S rDNA sequencing, but some phenotypic tests may be useful for this purpose.¹¹

In this study we report the isolation of a highly imipenem-resistant *B. xylanisolvens* strain, its phenotypic and molecular characterization and the description of its novel MBL gene and its prevalence.

Materials and methods

Bacterial strains and cultivation

B. xylanisolvens 18440 (Table 1) was isolated in 2016 from one of the microbiological samples of a patient diagnosed as having thoracic empyema as the main symptom and posterior wall infarction, which was resolved with bypass-operation surgery (2015). The therapy for the pleural empyema in 2016 included partial pleurectomy, drainage, Kerlix rolls and antibiotic treatment (piperacillin/tazobactam IV 3 × 4.5 g and after its insufficiency imipenem IV 3 × 1 g and later 4 × 0.5 g). Following these treatments and an 11 week hospital stay the patient's state improved and he returned home with regular wound observation and care.

Four hundred and four other *Bacteroides* strains were also included from two previous studies (see Table 1); one that screened imipenem-resistant *Bacteroides* strains from faeces in Hungary and the UK (4 strains, Study 1) and one that was a *Bacteroides* antibiotic resistance survey in Hungary in 2014–16 (400 strains, Study 2).^{8,12} The methods of bacterial cultivations and manipulations have been described previously.⁵

Antimicrobial susceptibility tests and carbapenemase assay

Antimicrobial susceptibilities were determined using Etest methodology, as recommended by the supplier (bioMérieux), or agar dilution in the case

of the 400 clinical *Bacteroides* and *Parabacteroides* strains (Study 2; Table 1). Carbapenemase production by *B. xylanisolvens* 14880 was measured as described previously.⁸

WGS and bioinformatic analyses

WGS of *B. xylanisolvens* 14880 was performed using Illumina mate-paired sequencing technology, the resulting sequence was submitted to GenBank (www.ncbi.nlm.nih.gov, acc. no. PRJNA481227) and the WGS data were further analysed using ResFinder and IslandViewer 4 for the presence of antibiotic resistance genes (80% coverage and 30% homology parameters) and genomic islands, respectively.^{13,14}

Determination of the promoter of *crxA* in *B. xylanisolvens* 14880

5'-RACE was used to determine the transcription initiation site of the *crxA* gene in *B. xylanisolvens* 14880 using a kit (Roche) (using steps as recommended by the supplier). Template total RNA was isolated using the HighPure RNA Isolation Kit (Roche) and the contaminating DNA was digested using DNase I (Thermo Fisher Scientific). The sequences of the gene-specific primers are given in Table S1 (available as Supplementary data at JAC Online) with the corresponding annealing temperatures used in the PCR steps in 50 µL final volumes using the DreamTaq endpoint PCR Master Mix (Thermo Fisher Scientific). The RACE PCR fragment was inserted into the pJET2.1 vector (Thermo Fisher Scientific) and the resulting constructs were sequenced using Sanger capillary sequencing (Life Technologies).

Table 1. List of strains and the results of examinations of the prevalence and activation mechanisms of *crxA* genes in *Bacteroides* strains

Study/strains	identification using MALDI-TOF MS	identification using <i>rpoB</i> sequencing	Imipenem MIC (mg/L)	<i>crxA</i>	IS1380-like IS	<i>crxA</i> upstream region ^a
<i>B. xylanisolvens</i> 14880 Study 1 ⁸	<i>B. xylanisolvens</i>	<i>B. xylanisolvens</i>	128	+	+	+ (1.8 kb)
<i>B. fragilis</i> 3035	<i>B. fragilis</i>	NA	0.25 (4) ^b	–	NT	NA
<i>Bacteroides capillosus</i> 427/1	<i>Pseudoflavonifractor capillosus</i>	NA	2 (32) ^b	–	NT	NA
<i>Bacteroides distasonis</i> 22/1	<i>B. ovatus/xylanisolvens</i>	<i>B. xylanisolvens</i>	32	+	–	– (208 bp)
<i>Bacteroides vulgatus</i> 5/4	<i>B. vulgatus/dorei</i>	NA	2 (32) ^b	–	NT	NA
Study 2 ¹² (400 <i>Bacteroides</i> and <i>Parabacteroides</i> isolates)						
<i>B. ovatus/xylanisolvens</i> (n = 21)	<i>B. ovatus/xylanisolvens</i> (n = 3)	<i>B. ovatus</i> (n = 3)	NT	–	NT	NA
	<i>B. xylanisolvens</i> (n = 15)	<i>B. xylanisolvens</i> (n = 15)	NT	–	NT	NA
	<i>B. xylanisolvens</i> D85	<i>B. xylanisolvens</i>	0.5 (8) ^b	+	–	– (208 bp)
	<i>B. xylanisolvens</i> Sz9	<i>B. xylanisolvens</i>	0.125 (0.5) ^b	+	–	– (208 bp)
	<i>B. xylanisolvens</i> P8	<i>B. xylanisolvens</i>	2	+	+ (PCR mapping –) ^c	– (208 bp)

NA, not applicable; NT, not tested.

^aSizes of the amplified upstream fragments of the *crxA* genes are shown in parentheses.

^bHeterogeneous resistance phenotype; full inhibition zone is indicated first then the value where individual resistant colonies disappear is noted in parentheses.

^cThe strain contains an IS1380-like IS, but it could not be mapped to the *crxA* gene.

Table 2. Carbapenem MICs of the upstream constructs of *crxA* from *B. xylanisolvans* 14880 in *B. fragilis* 638R^a

Carbapenem	construct	MIC (mg/L)			
		pFD288 (empty vector)	pBCX12	pBCX-A2	pBCX-C6 (with promoter)
Imipenem	0.032	0.032	2	0.25	32
Meropenem	0.032	0.032	0.25	0.125	32

^aFor the 5' end of the constructs also see Figure S2.

Gene transfer and PCR experiments

The *crxA* gene was amplified by PCR using different lengths of upstream regions (Table 2 and Figure S1), digested using BamHI and ligated into the BamHI site of the *Bacteroides-Escherichia coli* shuttle vector pFD288.¹⁵ The ligation mixtures were transformed by electroporation into the *E. coli* DH5 α strain and the construct was transferred into the *B. fragilis* 638R host using triparental mating.¹⁵

PCR experiments were carried out as described previously⁸ and the primer sequences and PCR conditions are given in Table S1.

Results and discussion

B. xylanisolvans 14880 was found to have the following MICs: imipenem, 128 mg/L; meropenem, >32 mg/L; ertapenem, >32 mg/L; doripenem, >32 mg/L; and imipenem/EDTA, 1 mg/L (the latter suggesting an MBL phenotype). Carrying out *cfiA* PCR on *B. xylanisolvans* 14880 yielded a negative result, but it produced 185 U/mg specific imipenemase activity. To investigate this carbapenem resistance mechanism, WGS and bioinformatic analyses were performed and antimicrobial susceptibilities were determined using Etest methodology (Table S2). The full genomic sequence obtained for *B. xylanisolvans* 14880 was 6.01 Mbp and it was resistant to only β -lactams (Table 2). Antibiotic resistance genes were detected using ResFinder and thus some known antibiotic resistance genes were revealed (Table S2). An ORF was also detected that belonged to the class B1 MBL group and had 37.3% identity and 82.3% similarity to CfiA (see Table 2 and Figure S1) at the protein level. The genomic sequence also revealed an IS1380-like IS element in its upstream region. Using 5'-RACE, we were able to determine the transcriptional start site 160 nt upstream of its start codon (Figure S2). Its gene transfer with various upstream sequences by triparental mating to a carbapenem-susceptible host (*B. fragilis* 638R) demonstrated that it could confer carbapenem resistance and therefore it was termed *crxA* (carbapenem resistance protein of *B. xylanisolvans*). Notably, the construct harbouring the IS1380-like IS promoter was able to increase the imipenem/meropenem MIC for the susceptible host strain 1000-fold (Table 2).

Despite the low identity value between CrxA and CfiA (37.3%), we managed to locate within CrxA the amino acid residues that make up the active centre of CfiA¹⁶ (Figure S1) and CrxA also harboured a C-terminal tail of 101 amino acids (Figure S1) compared with CfiA, but the effect of all the main differences on the enzymatic activity (e.g. substrate specificity and kinetic parameters) needs to be clarified in a future study.

IslandViewer located several putative chromosomal elements/islands in the genome of *B. xylanisolvans* 14880 (Figure S3), of which one is for *crxA* (Figure S4). In the *crxA* 'element' and in its vicinity there are regulatory genes, IS elements (IS1380 and IS110-like ISs) and addiction toxin genes (Fic, GNAT) too. These and especially the latter make it somewhat similar to the *cfiA* gene island, which also contains a suspected GNAT toxin gene.

We also wished to determine the prevalence of *crxA* among *Bacteroides* spp.; strains from two earlier studies were screened for it by RT-PCR. Of the three non-*fragilis* *Bacteroides* strains of the first study, the *B. xylanisolvans* 22/1 strain proved to be positive, while of the strains of the second study, three *B. xylanisolvans* strains were positive (Table 1). We designed primers to detect the IS upstream of *crxA* in the latter strains, but a real activating one was just found in *B. xylanisolvans* 14880 (Table 1). Since MALDI-TOF MS cannot differentiate *B. ovatus* and *B. xylanisolvans* well, we used *rpoB* sequencing to determine the exact species identifications of the *B. ovatus/xylanisolvans* strains from the above two studies (Table 1). All the strains containing *crxA* turned out to be *B. xylanisolvans*, so we concluded that *crxA* is specific for *B. xylanisolvans* and estimated its prevalence among clinical *B. xylanisolvans* isolates in Hungary at 16.7% (3/18 *crxA*-positive *B. xylanisolvans*; Table 1).

Previously, the main carbapenem-resistant *Bacteroides* isolates were *B. fragilis*. Studies examining the faecal microbiota detected a significant proportion of resistant *Bacteroides* strains. In a recent study in our laboratory using selective media for *Bacteroides* isolation with (4 mg/L) and without meropenem, we found that about 1% of the cultivable *Bacteroides* population is resistant to carbapenems.¹⁷ Hansen *et al.*¹⁸ also noticed that after carbapenem treatment the prevalence of carbapenem-resistant *Bacteroides* strains increased in the normal microbiota of the treated patients and the majority of these strains were *B. xylanisolvans*. Recently some studies reported and characterized a few non-*fragilis* *Bacteroides* species isolates as carbapenem resistant,^{9,19} but this study is the most complete in characterization of the resistance mechanism.

Conclusions

Overall, we can state that *B. xylanisolvans*, a non-*fragilis* *Bacteroides* species, can also harbour a carbapenem resistance mechanism that is similar to the *B. fragilis* *cfiA* system (MBL, IS element activation, a GNAT toxin gene-containing genetic element and a similar prevalence of 'silent' and resistant cases). Hence, as demonstrated by our current case and measured prevalences, carbapenem-resistant *Bacteroides* strains other than *B. fragilis* should not be ignored in the clinics.

Acknowledgements

We are grateful to Dr Katalin Kristóf, Dr Emese Juhász, Dr Cecilia Misztó, Dr Krisztina Latkóczy, Dr Szilvia Zsófia Melegh and Dr Edit Urbán for providing the Study 2 *Bacteroides* strains.

Funding

This study was supported by the Albert Szent-Györgyi Research Fund from the Albert Szent-Györgyi Medical School, University of Szeged.

Transparency declarations

None to declare.

Supplementary data

Tables [S1](#) and [S2](#) and Figures [S1](#) to [S4](#) are available as [Supplementary data](#) at JAC Online.

References

- 1** Wexler HM. *Bacteroides*: the good, the bad, and the nitty-gritty. *Clin Microbiol Rev* 2007; **20**: 593–621.
- 2** Sóki J. Extended role for insertion sequence elements in the antibiotic resistance of *Bacteroides*. *World J Clin Infect Dis* 2013; **3**: 1–12.
- 3** Jurėnas D, Garcia-Pino A, Van Melderen L. Novel toxins from type II toxin-antitoxin systems with acetyltransferase activity. *Plasmid* 2017; **93**: 30–5.
- 4** García N, Gutiérrez G, Lorenzo M et al. Gene context and DNA rearrangements in the carbapenemase locus of division II strains of *Bacteroides fragilis*. *Antimicrob Agents Chemother* 2009; **53**: 2677–8.
- 5** Sóki J, Hedberg M, Patrick S et al. Emergence and evolution of an international cluster of MDR *Bacteroides fragilis* isolates. *J Antimicrob Chemother* 2016; **71**: 2441–8.
- 6** Snyderman DR, Jacobus NV, McDermott LA et al. National survey on the susceptibility of *Bacteroides fragilis* group: report and analysis of trends in the United States from 1997 to 2004. *Antimicrob Agents Chemother* 2007; **51**: 1649–55.
- 7** Hurlbut S, Cuchural GJ, Tally FP. Imipenem resistance in *Bacteroides distasonis* mediated by a novel β -lactamase. *Antimicrob Agents Chemother* 1990; **34**: 117–20.
- 8** Sóki J, Edwards R, Urbán E et al. Screening of isolates from faeces for carbapenem-resistant *Bacteroides* strains; existence of strains with novel types of resistance mechanisms. *Int J Antimicrob Agents* 2004; **24**: 450–4.
- 9** Sadarangani SP, Cunningham SA, Jeraldo PR et al. Metronidazole- and carbapenem-resistant *Bacteroides thetaiotaomicron* isolated in Rochester, Minnesota, in 2014. *Antimicrob Agents Chemother* 2015; **59**: 4157–61.
- 10** Chassard C, Delmas E, Lawson PA et al. *Bacteroides xylanisolvens* sp. nov., a xylan-degrading bacterium isolated from human faeces. *Int J Syst Evol Microbiol* 2008; **58**: 1008–13.
- 11** Pedersen RM, Marmolin ES, Justesen US. Species differentiation of *Bacteroides dorei* from *Bacteroides vulgatus* and *Bacteroides ovatus* from *Bacteroides xylanisolvens* - back to basics. *Anaerobe* 2013; **24**: 1–3.
- 12** Sárvári KP, Sóki J, Kristóf K et al. A multicentre survey of the antibiotic susceptibility of clinical *Bacteroides* species from Hungary. *Infect Dis (Lond)* 2018; **50**: 372–80.
- 13** Bortolaia V, Kaas RS, Ruppe E et al. ResFinder 4.0 for predictions of phenotypes from genotypes. *J Antimicrob Chemother* 2020; **75**: 3491–500.
- 14** Bertelli C, Laird MR, Williams KP et al. IslandViewer 4: expanded prediction of genomic islands for larger-scale datasets. *Nucleic Acids Res* 2017; **45**: W30–5.
- 15** Smith CJ, Rollins LA, Parker AC. Nucleotide sequence determination and genetic analysis of the *Bacteroides* plasmid, pBI143. *Plasmid* 1995; **34**: 211–22.
- 16** Concha NO, Rasmussen BA, Bush K et al. Crystal structure of the wide-spectrum binuclear zinc β -lactamase from *Bacteroides fragilis*. *Structure* 1996; **4**: 823–36.
- 17** Sóki J, Wybo I, Hajdú E et al. A Europe-wide assessment of antibiotic resistance rates in *Bacteroides* and *Parabacteroides* isolates from intestinal microbiota of healthy subjects. *Anaerobe* 2020; **62**: 102182.
- 18** Hansen KCM, Schwensen SAF, Henriksen DP et al. Antimicrobial resistance in the *Bacteroides fragilis* group in faecal samples from patients receiving broad-spectrum antibiotics. *Anaerobe* 2017; **47**: 79–85.
- 19** Kaeuffer C, Ruge T, Diancourt L et al. First case of bacteraemia due to carbapenem-resistant *Bacteroides faecis*. *Antibiotics (Basel)* 2021; **10**: 319.